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Vaccines are essential to control the spread of severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) and to protect the vulnerable population. However, one
safety concern of vaccination is the possible development of antibody-dependent
enhancement (ADE) of SARS-CoV-2 infection. The potential infection of Fc receptor
bearing cells such as macrophages, would support continued virus replication and
inflammatory responses, and thereby potentially worsen the clinical outcome of COVID-
19. Here we demonstrate that SARS-CoV-2 and SARS-CoV neither infect human
monocyte-derived macrophages (hMDM) nor induce inflammatory cytokines in these
cells, in sharp contrast to Middle East respiratory syndrome (MERS) coronavirus and the
common cold human coronavirus 229E. Furthermore, serum from convalescent COVID-
19 patients neither induced enhancement of SARS-CoV-2 infection nor innate immune
response in hMDM. Although, hMDM expressed angiotensin-converting enzyme 2, no or
very low levels of transmembrane protease serine 2 were found. These results support the
view that ADE may not be involved in the immunopathological processes associated with
COVID-19, however, more studies are necessary to understand the potential contribution
of antibodies-virus complexes with other cells expressing FcR receptors.
Keywords: human coronaviruses, SARS-CoV-2, COVID-19 convalescent sera, ADE, human monocyte-
derived macrophagesINTRODUCTION
Since the emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in
December 2019 in the Chinese city of Wuhan, the virus has spread globally causing the coronavirus
disease 2019 (COVID-19) pandemic. The high morbidity and severity of COVID-19 in some of the
affected patients have jeopardized the public health system of affected countries. In addition, the
public health measures that have been implemented to control the pandemic have affected the life
and economy of millions of people around the world.gy | www.frontiersin.org April 2021 | Volume 11 | Article 6445741
Garcı́a-Nicolás et al. SARS-CoV-2 ADE in hMDMIn the current situation, the lack of neutralizing antibodies
against SARS-CoV-2, allows the virus to spread rapidly in the
human population. A global vaccination campaign may have the
potential to finally control the pandemic and vaccination
programs have started recently. However, a concern is the
possibility that vaccination could promote antibody-dependent
enhancement (ADE) of SARS-CoV-2 infection which could be
associated with enhancement of the disease (Lee et al., 2020).
The underlying mechanism of ADE of infection is based on the
interaction between virion-antibody complexes and Fc gamma
receptors (FcgR) that are expressed by cells of the immune system
such asmacrophages. The binding of virion-antibody complexes to
Fc receptors could result in their uptake into the cells by receptor-
mediated endocytosis leading to potential infection of the cells
(Taylor et al., 2015). Despite speculation and alarming about this
possibility at the time of initiation of our work, no data were
published specifically addressing ADE of SARS-CoV-2 (Lee et al.,
2020; Rogers et al., 2020). With this in mind, the present study
aimed to investigate whether immune sera from convalescent
COVID-19 patients would enhance SARS-CoV-2 infection and
promote secretion of pro-inflammatory cytokines production by
human macrophages. To this end we performed a comparative
study on the susceptibility of humanmacrophages to infectionwith
human coronavirus 229E (HCoV-229E), Middle East respiratory
syndrome coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-
2 and the inflammatory cytokine response of these cells. Potential
ADE of infections by SARS-CoV and SARS-CoV-2 were studied
using immune sera from convalescent COVID-19 patients.MATERIAL AND METHODS
Ethics Statement
Buffy coats from anonymous healthy blood donors were obtained
from the regional transfusion blood service of the Swiss Red Cross
(SRC) (Bern, Switzerland). The use of buffy coats was approved by
the SRC review board. All serum samples employed in this study
were collected following the guidanceof theAct onMedicalDevices
(MPG guideline 98/79/EC) for the collection of human residual
material to evaluate suitability of an in vitro diagnostic medical
device (§24). For this study an informed consent and ethical
approval was not needed because only leftovers of serum samples
for diagnostic laboratory procedures were used.Cells
Vero cells (E6 and B4 lineages, African Green monkey kidney
epithelial cells) and Huh-7 cells (human hepatocellular carcinoma
cells) were cultured in Dulbecco’s minimal essential medium
(DMEM; Life Technologies), supplemented with 10% fetal bovine
serum (FBS), non-essential amino acids (Life Technologies),
penicillin-streptomycin (Gibco) and HEPES (Gibco). A549
(adenocarcinomic human alveolar basal epithelial cells) stably
transfected with angiotensin-converting enzyme 2 (ACE2) and
transmembrane protease serine 2 (TMPRSS2) were purchased
from Invivogen (Toulouse, France) and cultured in minimal
essential medium (MEM) supplemented with 10% FBS, 0.5 mg/mlFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2of puromycin (Invivogen) and 300 mg/ml of hygromycin B
(Invivogen). A. albopictus C6/36 cells (ATCC® CRL-1660™) were
cultured in MEM (Gibco) supplemented with 100 mM of sodium
pyruvate (Gibco), non-essential amino acids and 10% FBS
For the production of human monocyte derived macrophages
(hMDM), peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats by density gradient centrifugation on
Ficoll-Paque™ PLUS (1.077 g/L; GE healthcare). Then, monocytes
were sorted using anti-CD14 beads as proposed by the
manufacturer (Miltenyi Biotech GmbH), and seeded in 24 well
plates at 2.5 x 105 cells/well in 500 µl of Roswell Park Memorial
Institute (RPMI) 1640 medium (Gibco) and kept at 37°C and 5%
CO2 atmosphere for one hour. Non-adherent cells were removed
and 500 µl of RPMI 1640 supplemented with 10% of FBS (Gibco),
GlutaMAX (Gibco), penicillin-streptomycin (Gibco) and human
M-CSF (100 ng/ml; Miltenyi Biotec) were added. The cells were
cultured for six days at 37 °C and 5% CO2. The full medium
complemented with M-CSF was replaced every 48 to 72 hours.
Viruses
A collection of different coronaviruses was employed for the
experiments of the present study including the human
coronavirus 229E [HCoV-299E; (Thiel et al., 2001)], Middle East
respiratory syndrome coronavirus [MERS-CoV, strain EMC/2012;
(van Boheemen et al., 2012)], SARS-CoV [Frankfurt-1; (Thiel et al.,
2003)] and SARS-CoV-2 (SARS-CoV-2/München-1.1/2020/929)
kindly provided by Daniela Niemeyer, Marcel Müller, and
Christian Drosten (Charité, Berlin, Germany). HCoV-299E was
propagated in Huh-7 cells in DMEM supplemented with 5% of FBS
and non-essential amino acids at 33°C. MERS-CoV was propagated
in Vero B4 cells in MEM supplemented with 2% of FBS and non-
essential amino acids at 37°C. For the propagation of SARS-CoV
and SARS-CoV-2 Vero E6 cells in MEM supplemented with 2% of
FBS and non-essential amino acids at 37°C was employed. All
coronavirus titrations were performed by end point dilution (ten-
fold serial dilutions of viral supernatants) taking advantage of the
virus-induced cytopathic effect that was apparent 56 to 72 hours
post infection (hpi). Virus titers were expressed as 50% tissue culture
infective dose per ml (TCID50/ml). As a positive control for ADE of
infection, we used Japanese encephalitis virus (JEV) (Laos strain;
GenBank CNS769_Laos_2009; kindly provided by Prof. Remi
Charrel, Aix-Marseille Université, Marseille, France) with immune
sera previously described (Garcia-Nicolas et al., 2017).
Infection With Coronaviruses
Vero E6 cells or hMDM were incubated for 1.5 h at 39°C or 37°C
with the respective virus using amultiplicity of infection (MOI) of 1
TCID50 per cell, including mock control. Subsequently, the virus
inoculum was removed, the cells washed three times with warm
phosphate buffered saline (PBS), andRPMImedium supplemented
with 2% FBS was added to the cells. As a positive control for the
induction of pro-inflammatory cytokines either 1 µg/ml of
lipopolysaccharide (LPS; Sigma-Aldrich) or 10 mg/ml of
polyinosinic-polycytidytic acid (poly I:C, Sigma-Aldrich) were
added to the cell culture medium. As indicated for each
experiment, after 24, 48 or 72 h, supernatants were collected and
stored at -70°C.April 2021 | Volume 11 | Article 644574
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Human macrophages and A549 cells stably transfected with
human ACE2 and human TMPRSS2 were harvested using
TrypLETMSelect (Gibco) for 20 min at room temperature and
washed with CellWash solution (Becton Dickinson).
Subsequently, the cells were stained for 20 min with anti-
human TMPRSS2 monoclonal antibody (P5H9-A3, Santa Cruz
biotechnology) and anti-human ACE2 antibody (A20069,
BioLegend) in CellWash. After a washing the cells with
CellWash, they were incubated for 10 min with anti-rat Alexa
488 fluorochrome conjugate (ThermoFisher Scientific) and
Alexa Fluor 647 conjugated anti-mouse IgG1 (ThermoFisher
Scientific). Finally, cells were analyzed by flow cytometry using a
FACSCantoII (Becton Dickinson). Data analysis was performed
with Flowjo V.9.1 software (Treestars, Inc.). Dead cells were
excluded by electronic gating in forward/side scatter plots,
followed by exclusion of doublets.
Antibody-Dependent Enhancement
of Infection
A collection of sera from COVID-19 convalescent patients from
a previously published work was employed for the present study
(Zettl et al., 2020). This included sera with a broad range of
neutralization titers against SARS-CoV-2 (ND50 <1:10; 1:20;
1:160; 1:240 and 1:2560). In order to test the ADE potential of
these sera, different serum dilutions (1:10; 1:100; 1:1000 and
1:10000) were incubated for 30 min at 37°C with an equal
volume of viral suspension (SARS-CoV or SARS-CoV-2)
corresponding to a MOI of 1 TCID50/cell. Thereafter, the
virus/serum mixtures were added to human macrophages or
Vero E6 cells and incubated for 30 min at 37°C and 5% CO2
atmosphere. The cells were washed three times with PBS before
fresh medium was added. As a control for ADE of infection, we
employed a serum from immunized pigs known to have a high
capacity of inducing ADE of infection for JEV in macrophages
(Garcia-Nicolas et al., 2017). The serum (ND50 of 1:160 for JEV
Laos) was serially diluted (1:10; 1:100; 1:1000 and 1:10000) and
incubated at 37°C for 30 min with JEV Laos at a MOI of 1
TCID50/cell. Porcine naïve serum was included as control. After
that, virus/serum mixtures were added on hMDM and incubated
for 30 min at 37°C, washed off and fresh medium was added.
After 24 h of incubation at 37°C viral infectivity was determined
by means of flow cytometry as described below.
Determination of Infected Cells
For immunofluorescence microscopy, cells were fixed with 4%
formaldehyde for 10 min at room temperature, washed with PBS,
and permeabilized with 0.3% saponin (PanReac AppliChem).
The permeabilization procedure was performed for 20 min on ice
in the presence of J2 monoclonal antibody directed to dsRNA
(English and Scientific Consulting), or some experiments a rabbit
antibody directed to the SARS-CoV nucleocapsid (N) protein
(Rockland-inc) was included in this step. Subsequently, the cells
were washed with 0.1% saponin, and cells were incubated for
20 min on ice with Alexa Fluor 488 conjugated anti-mouse IgG2aFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3(ThermoFisher Scientific) or with Alexa Fluor 546 conjugated
anti-rabbit (ThermoFisher Scientific) in 0.3% saponin. Cells were
washed once with PBS prior to incubation with 4′,6-diamidino-
2-phenylindole (DAPI; Sigma) for 5 min at 37 °C. Finally, the
percentage of infected cells was determined by enumerating the
dsRNA positive cells in 10 fields/well using an Axio Observer Z1
inverted microscope equipped with a Zeiss Colibri Illuminator
(CarlZeiss) and digital imaging Zeiss software (AxioVision, v4).
All generated images were analyzed using ImageJ software.
For the determination of infected cells by flow cytometry,
macrophages and Vero E6 cells were harvested using
TrypLETMSelect (Gibco) for 20 min at room temperature and
fixed with 4% (w/v) formaldehyde. Thereafter, the cells were
permeabilized/stained for 20 min on ice with 0.3% (w/v) saponin
in PBS in the presence of a rabbit antibody directed to the SARS-
CoV N protein (Rockland-inc). For some experiments we used
an anti-dsRNA monoclonal antibody (J2, English and Scientific
Consulting). For the determination of JEV infected cells anti-
flavivirus E protein mAb 4G2 (IgG2a) was employed as primary
antibody. The cells were subsequently washed, incubated for
10 min with anti-rabbit Alexa 488 or Alexa Fluor 647-conjugated
anti-mouse IgG2a (ThermoFisher Scientific) and analyzed by
flow cytometry (FACSCantoII, Becton Dickinson). For analysis,
Flowjo V.9.1 software (Treestars, Inc.) was used. Dead cells were
excluded by electronic gating in forward/side scatter plots,
followed by exclusion of doublets.
Determination of Cytokines
Cell culture supernatants were analyzed for the presence of the
following cytokines: Tumor necrosis factor (TNF), interferon
beta (IFN-b), interleukin 6 (IL-6) and IL-1b were quantified by
ELISA (R&D Systems) following the manufacturer’s instructions.
Detection limits were 30 pg/ml for TNF, 10 pg/ml for IFN-b, 4
pg/ml for IL-1b and 9 pg/ml for IL-6.
Statistics
For the generation of figures and data analyses the GraphPad
Prism 8 Software (GraphPad Software, Inc.) was employed. All
experiments were independently performed 3 to 6 times with
cells from different donors, and each experiment was run in
triplicates. For viral titrations, differences between groups were
assessed using a Kruskal–Wallis test, and for individual
differences the Mann–Whitney U-test with Bonferroni
correction as post hoc was employed. For group differences in
the percentages of infected cells and levels of cytokines
expression comparisons, a one-way ANOVA test with
Bonferroni correction as post hoc was performed. Correlation
analysis between infected cells, viral titers, and expressed
cytokines were calculated by Spearman’s Rho analysis; a
correlation between two different factors was considered
relevant with R2 >0.5. A p value lower than 0.05 was
considered statistically significant for every analyzed data. In
figure 1, different superscript letters indicate a significant
difference (p < 0.05) between the conditions. For the table
2 * indicates p <0.05, **p ≤0.002, ***p ≤0.001 and ****p ≤0.0001.April 2021 | Volume 11 | Article 644574
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Visualization of Coronavirus Replication by
Immunolabeling of dsRNA
Taking into account that dsRNA is a replication intermediate located
in double-membrane vesicles during coronavirus replication (Wolff
et al., 2020), coronavirus-infected cells may be specifically detected by
antibodies to dsRNA rather than by antibodies directed to viral
proteins. In order to evaluate the suitability of dsRNA
immunolabeling for this purpose, Vero E6 cells infected with either
SARS-CoV or SARS-CoV-2 at MOI of 1 TCID50/ml, were double-
stained for dsRNA and N protein, and analyzed by
immunofluorescence microscopy or flow cytometry (Figure 1).
While dsRNA staining allowed us to identify infected cells by
immunofluorescence microscopy to a similar degree as N protein
labeling (Figures 1A, B), flow cytometry only worked when the N
protein was labeled (Figure 1A). This experiment demonstrated that
immunolabeling of dsRNA allows the identification of cells infectedFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4with different coronaviruses by immunofluorescence microscopy in
the absence of antibodies specifically recognizing viral proteins. On
the other hand, the labeling of N protein in combination with flow
cytometry is an efficient way of detecting cells infected by SARS-CoV
or SARS-CoV-2.
Human Coronaviruses Differ in Their
Ability to Infect hMDM
Infection of hMDM with HCoV-299E, MERS-CoV, SARS-CoV
and SARS-CoV-2 at MOI of 1 TCID50/cell demonstrated high
susceptibility to infection with the common cold virus HCoV-229E,
low susceptibility to infection with the highly pathogenic
coronavirus MERS-CoV, and resistance to infection by SARS-
CoV and SARS-CoV-2, in terms of dsRNA immunostaining
(Figures 2A, B). Quantification of the number of infectious virus
particles in the cell culture supernatants showed that only HCoV-
229E and MERS-CoV replicated efficiently in hMDM (Figure 2C).
Although HCoV-229E showed higher percentages of infectedA
B
FIGURE 1 | Determination of SARS-CoV and SARS-CoV-2 infected hMDM by immunolabeling for dsRNA and N protein. Vere E6 cells were infected with SARS-
CoV and SARS-CoV-2 at MOI 1 TCID50/cell, and after 24 hpi dsRNA and N protein were labeled with specific antibodies. The nuclei were stained with DAPI. Then
positive cells for dsRNA and N were quantified either by flow cytometry or immunofluorescence microscopy (A). In (B) example of representative images acquired by
fluorescence microscopy is shown. The scale bar represent 40 µm. The data are from three independent experiments. Statistically significant differences between the
conditions are indicated by asterisks (ns indicates non-statistical differences, *p < 0.05, **p ≤ 0.002 and ****p ≤ 0.0001).April 2021 | Volume 11 | Article 644574
Garcı́a-Nicolás et al. SARS-CoV-2 ADE in hMDMhMDM (32.79% ± 18.79 SD) the highest virus titers were found in
the cell culture supernatant of macrophages infected with MERS-
CoV (Figure 2C). Nevertheless, it has to be taken into consideration
that all experiments were performed at 37°C although the optimal
temperature for HCoV-229E is 33°C (Dijkman et al., 2013). Viral
titers of SARS-CoV and SARS-CoV-2 were not statistically
significantly different compared to the mock control. The
background signal detected for some wells might be due to
remaining viral particles from the inoculum that stayed bound
to the hMDM surface and were not removed by washing the cells.
We also tested infectivity of hMDM to SARS-CoV or SARS-
CoV-2 at later time points, including 48 and 72 hpi. While
HCoV-229E efficiently infected hMDM neither SARS-CoV nor
SARS-CoV-2 were able to infect hMDM at any of the time points
(Figure 2D). Moreover, only HCoV-299E but not SARS-CoV
and SARS-CoV-2-infected hMDM showed a significant decrease
of the number of cells, indicating a virus-induced cytopathogenic
effect (Figure 2E).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5Human MDM Produce Cytokines
Following Infection With HCoV-229E
Human MDM infected by HCoV-229E, but not by MERS-CoV,
SARS-CoV or SARS-CoV-2, secreted TNF, and low levels of both
IFN-b and IL-6 (Figure 3). None of the tested coronaviruses
induced secretion of IL-1b. Taking into consideration that viral
RNA might induce innate immune responses, we tested the
correlation between the percentage of dsRNA positive cells, viral
titers and level of secreted cytokines. The results found a clear
association between the percentage of infected cells and secreted
cytokine levels but not with viral titers (Table 1).
Human MDM Express SARS-CoV-2
Receptor ACE2 but No or
Low Levels of TMPRSS2
First, as hMDM were resistant to infection by SARS-CoV-2, we
assessed the expression levels of the viral cell receptor ACE2, as well




FIGURE 2 | Susceptibility of hMDM to different human coronaviruses. Human MDM were inoculated with different coronaviruses (hCoV-229E, MERS-CoV, SARS-
CoV-1 and SARS-CoV-2) using an MOI of 1 TCID50/cell. Mock-infected cells were included as controls. After incubating the cells for 1.5 hours, the inoculum was
removed, the cells washed, and fresh medium added. At 24 hpi, dsRNA in the cells was detected with a specific antibody and nuclei were stained with DAPI; the
scale bar represents 40 µm. (A) The percentage of dsRNA-positive hMDM was calculated for 10 fields per condition (B). In (C) virus titers are shown. The same
experiment was repeated with hCoV-229E, SARS-CoV-1 and SARS-CoV-2, and infected cells were quantified at 24, 48 and 72 hpi (D). The relative number of total
hMDM per well was calculated taking as reference the number of cells at 24 hpi (E). The data from three independent experiments run in triplicates are shown in
each panel. Statistically significant differences between the conditions are indicated by different superscript letters in (B, C) (p < 0.05), and by asterisks in (D, E)
(****p ≤ 0.0001).April 2021 | Volume 11 | Article 644574
Garcı́a-Nicolás et al. SARS-CoV-2 ADE in hMDMof the spike protein (Hoffmann et al., 2020; Shang et al., 2020). For
that, double immunolabeling of cell ACE2 and TMPRSS2 was
performed in hMDM after differentiation, and their expression
was assessed by flow cytometry (Figure 4); A549 cells transfected
with ACE2 and TMPRSS2 were used as positive control. This
experiment showed that hMDM express high levels of ACE2 (33.3%
± 8.25SD; Figure 4A) comparable to the A549 cells transfected with
ACE2 and TMPRSS2 (29.8% ± 3.55SD; Figure 4A). On the other
hand, the percentage of TMPRSS2 positive hMDM was very low
(3.03% ± 2.17SD; Figure 4A) when compared to the A549 cells
transfected with ACE2 and TMPRSS2 (25.3% ± 2.66SD; Figure
4A). These results indicate that although hMDM express the SARS-
CoV-2 receptor ACE2, the lack of expression of TMPRSS2 might
prevent infection.
Antibodies From Convalescent COVID-19
Patients Neither Induce Antibody-
Dependent Enhancement of Infection of
hMDM With SARS-COV-2 Nor Promote
Cytokine Responses
First, as a positive control for ADE in hMDM, sera from
immunized pig that were previously demonstrated to induce a
high ADE of JEV in porcine MDM (Garcia-Nicolas et al., 2017)
were used. Despite the low binding of porcine IgGs to human
FcR (Antonsson and Johansson, 2001), this experiment showed
that such JEV immune complexes can enhance the infection of
hMDM (Supplementary Figure 1) compared with both the JEV
Laos control for the infection and the same dilution for the naïveFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6porcine serum. This experiment showed the validity of the
methodology to test ADE of infection in hMDM.
Next, selected COVID-19 sera with a neutralization titer
below 1:10 and with a neutralization titer of 1:240, were
diluted serially from 1:10 to 1:1000, mixed with SARS-CoV
and SARS-CoV-2, and then added to Vero E6 cells. Both sera
demonstrated a dilution-dependent inhibition of SARS-CoV-2
infection. In addition, a cross-reactivity of COVID-19
convalescent patient sera with SARS-CoV-1 was observed,
confirming previous reports (Zettl et al., 2020) (Table 2).
Using the same approach, a larger collection of sera from
COVID-19 convalescent patients with neutralization titers
ranging from <10 to 1:2560 was incubated at different
concentrations with SARS-CoV and SARS-CoV-2 and added
to hMDM. Importantly, with none of the tested serum dilutions
which went up to 1:10000 infection of hMDM was observed.
Moreover, hMDM exposed to virus-antibodies complexes did
not secrete any detectable pro-inflammatory cytokines (Table 2).
These results indicate that the potential uptake of SARS-CoV
and SARS-CoV-2 via FcR does not result in infection and
activation of human macrophages.DISCUSSION
A first observation of the present study was that in contrast to the
common cold virus hCoV-229E and MERS-CoV, SARS-CoV and
SARS-CoV-2 were unable to infect hMDM. The receptor for SARS-A B C
FIGURE 3 | Human MDM immune response after coronavirus infection. Human MDM were inoculated with different coronaviruses (hCoV-229E, MERS-CoV, SARS-
CoV-1 and SARS-CoV-2) as described before. Mock-infected cells or cells treated with LPS or poly I:C served as controls. After 24 hpi TNF (A) IFN-b (B) and IL-6
(C) were determined in the cell culture supernatants. The data from three independent experiments run in triplicates are shown. Different superscript letters indicate a
significant difference (p < 0.05) between the conditions.TABLE 1 | Correlation analysis between dsRNA positive hMDM, infectious virus titers and pro-inflammatory cytokines.
R2 Viral titer TNF IFN-b IL-6
dsRNA 0.015 0.821**** 0.682**** 0.892****
Viral titer – 0.004 0.006 0.001
TNF – 0.490**** 0.795****
IFN-b – 0.729****April 2021 | Volume 11 | Articl****p ≤ 0.0001.e 644574
Garcı́a-Nicolás et al. SARS-CoV-2 ADE in hMDMCoV-2 is angiotensin-converting enzyme 2 (ACE2) typically
expressed on ciliated epithelial cells, goblet cells, type II alveolar
pneumocytes as well as other cells from different organs as
enterocytes (Sungnak et al., 2020). However, there are conflicting
reports on the infection of human macrophages by SARS-CoV.
While one study described very limited ACE2 expression byFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7macrophages (Sungnak et al., 2020), another report postulated
that the receptor is expressed on tissue resident macrophages
(Song et al., 2020). Although we showed in the present study that
about 30% of the hMDM express ACE2 under the described
culture/differentiation conditions, hMDM were not permissive to
SARS-CoV or SARS-CoV-2. Of note, the expression of a truncatedA B
FIGURE 4 | ACE2 and TMPRSS2 expression in hMDM. After 6 days of differentiation ACE2 and TMPRSS2 were immunolabeled with specific antibodies and
positive cells were assessed by flow cytometry. A549 cells transfected with ACE2 and TMPRSS2 were used as control (A). Representative histograms for each
marker in the analyzed cells are shown (B). The data from 5 different human donor hMDM run in triplicates are shown. Statistically significant differences in the
expression of each marker between both cell types are marked by asterisks (****p ≤ 0.0001).TABLE 2 | Summary data for virus neutralization on Vero E6 cells and antibody-dependent enhancement of infection or cytokine response by hMDM for SARS-CoV
and SARS-CoV-2-antibody complexes”+” detected; “-” not detected; “NT” not tested.
Neutralization (% N+ Vero E6 cells n = 3) ADE (% N+ hMDM n = 6) Cytokine response (hMDMn = 6)
SARS-CoV SARS-CoV-2 SARS-CoV SARS-CoV-2 TNF (pg/ml) IFN-b (pg/ml)
Infection CTRL (%) 34 (± 1.5) 22.17 (± 2.11) – – – –
Immune serum Neutralizing titer Serum dilution
A < 1:10 1:10 10.41 (± 0.86)**** 7.07 (± 0.23)**** – – – –
1:100 29.67 (± 3.99) 15.26 (± 1.92)**** – – – –
1:1000 36.57 (± 2.59) 23.40 (± 2.55) – – – –
1:10000 34.23 (± 2.41) 32.93 (± 0.25) – – – –
B 1:20 1:10 NT NT NT – – –
1:100 NT NT NT – – –
1:1000 NT NT NT – – –
1:10000 NT NT NT – – –
C 1:160 1:10 NT NT NT – – –
1:100 NT NT NT – – –
1:1000 NT NT NT – – –
1:10000 NT NT NT – – –
D 1:240 1:10 10.08 (± 1.06)**** 0.25 (± 0.26)**** – – – –
1:100 25.63 (± 1.63)*** 2.25 (± 0.34)**** – – – –
1:1000 31.6 (± 0.72) 12.07 (± 0.58)**** – – – –
1:10000 32.93 (± 0.25) 18.73 (± 1.19)* – – – –
E 1:2560 1:10 NT NT NT – – –
1:100 NT NT NT – – –
1:1000 NT NT NT – – –
1:10000 NT NT NT – – –April 2021 | Volume 11Statistically significant differences compared to the control are indicated as: * for p < 0.05, *** for p ≤ 0.001 and **** for p ≤ 0.0001.| Article 644574
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stimulation or viral infection (Onabajo et al., 2020). While
remaining biologically active, dAEC2 does not facilitate SARS-
CoV-2 spike binding and does not serve as an entry receptor.
Whether hMDM express dACE2 remains to be formally
determined. Following attachment of virions to the cell surface,
the spike protein may be proteolytically activated and is able to
trigger membrane fusion and release of the viral genome into the
cytosol of the host cell. The proteolytic cleavage by TMPRSS2 or
related enzymes normally takes place at the cell surface as well as the
subsequent membrane fusion (Hoffmann et al., 2020). In the
absence of TMPRSS2, SARS-CoV and SARS-CoV-2 may be
proteolytically activated following receptor-mediated endocytosis
by cathepsin B/L (Hoffmann et al., 2020; Shang et al., 2020). The
present study shows that TMPRSS2 is expressed at very low levels in
hMDM, which is in line with a previous publication describing very
limited expression of TMPRSS2 expression in human macrophages
(Sungnak et al., 2020). Therefore, we speculate that this might be an
important limiting factor for the viral entry in macrophages.
Moreover, recently it has been described that the p41 invariant
chain of CD74 (major histocompatibility complex class II) can
inhibit the cathepsin-mediated cleavage of viral envelope proteins
(Bruchez et al., 2020). As macrophages constitutively express CD74
(Cho and Roche, 2013) the presence of the p41 invariant chain
might block the activity of cathepsin B/L contributing to the
resistance of hMDM to the infection by SARS-CoV and SARS-
CoV-2. In COVID-19 patients, the viral nucleoprotein N has been
detected in macrophages from lymphoid organs of COVID-19
patients (Park, 2020), but it is not clear whether this was caused
by direct infection or as a consequence of phagocytosis of
infected cells.
The infection of hMDM by HCoV-229E is in line with the
expression by these cells of aminopeptidase N (CD13), the cellular
receptor for HCoV-229E (Yeager et al., 1992). It is also in agreement
with previous reports describing the infection of alveolar
macrophages by HCoV-229E (Funk et al., 2012). The cellular
receptor for MERS-CoV dipeptidyl peptidase-IV (DPP4 also
known as CD26) is expressed at low levels by human monocytes
andmacrophages of healthy donors (Wang et al., 2013; Zhong et al.,
2013; Rao et al., 2018; Rao et al., 2019), which could explain MERS-
CoV infection of hMDM in our experiments.
Our results are also in line with a previous report
demonstrating that following infection with HCoV-229E
human macrophages strongly secrete TNF, but also produce
IL-6 and some IFN-b (Funk et al., 2012). Finally, we also noticed
a poor innate immune response of macrophages following
infection with MERS-CoV, confirming a previous report that
showed similar results (Zhou et al., 2014).
While writing the present manuscript contradictory data were
published claiming that SARS-CoV-2 induces an immune
activation of hMDM (Zheng et al., 2020). These conflicting
results might be the consequence of different methodologies used.
Whileweemployedpurifiedmonocytes togeneratemacrophages in
six days, Zheng and collaborators kept PBMCwithM-CSF for four
days and then for another 10 days when the cells became adherent
(Zheng et al., 2020). Another important methodological differenceFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8is that our study used ELISA to detect cytokines while Zheng and
collaborators analyzed mRNA by RT-PCR. As the levels of mRNA
induction foundwere rather low (fold change increase below 0.3), it
is possible that protein detection by ELISA would have been below
the detection limit as well.We are therefore proposing that hMDM
generated frompuremonocytes are not permissive to SARS-CoV-2
infection and do not mount inflammatory responses. This is in
contrast to HCoV-229E and the TLR ligand controls. While future
studies expanding to tissue macrophages are important, our results
indicate that proinflammatory responses observed during COVID-
19 may not be the result of macrophage infection but rather
originate from other innate immune cells or a complex
interaction between different immune cells which could include
macrophages. Therefore, to understand these eventsmore immune
cells such as plasmacytoid dendritic cells that are at the frontline of
the antiviral cytokine responses should be investigated.
In view of a potential link between ADE and inflammation
during COVID-19 in the presence of antibodies, we tested this
hypothesis using hMDM. With the selected sera from convalescent
COVID-19 patients and the described conditions, even at very high
serum dilutions and with sera that had low levels of neutralizing
antibodies, we did not find evidence for antibody mediated
enhancement of macrophage infection or pro-inflammatory
cytokine responses. Interestingly, sera of COVID-19 convalescent
patients showed cross-reactivity to SARS-CoV (Zettl et al., 2020),
despite that the sera did not enhance infection of hMDM by this
virus. This is in line with a previous report showing that the
presence of cross-reacting antibodies against SARS-CoV-2,
originating from previous endemic coronavirus infections, were
not linked with more severe COVID-19 (Ng et al., 2020).
Furthermore, in vaccination/challenge experiments carried out in
macaques no signs of enhanced disease were detected (Gao et al.,
2020; Yu et al., 2020). Finally, COVID-19 patients treated with
plasma transfusion from convalescent patients did not show signs of
disease aggravation (Casadevall and Pirofski, 2020; Joyner et al.,
2020). Altogether, these data are in line with our findings,
demonstrating that hMDM are not infected or activated by
SARS-CoV-2 neither by direct contact nor mediated by
antibodies from convalescent COVID-19 patients. Although the
lack of hMDM infection by SARS-CoV and SARS-CoV-2 provides
evidence of a lack of ADE, our study cannot exclude ADE effects on
other FcR-expressing cells as well as a possible role of the
complement system or T-cell mediated inflammation.DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in
the article/Supplementary Material. Further inquiries can be
directed to the corresponding author.ETHICS STATEMENT
Ethical review and approval was not required for the study on
human participants in accordance with the local legislation andApril 2021 | Volume 11 | Article 644574
Garcı́a-Nicolás et al. SARS-CoV-2 ADE in hMDMinstitutional requirements. Written informed consent for
participation was not required for this study in accordance
with the national legislation and the institutional requirements.AUTHOR CONTRIBUTIONS
OG-N, PV’K, and AS: conceptualization. OG-N, PV’K, FZ, GZ,
VT and AS: methodology. OG-N, PV’K and FZ: investigation.
OG-N, PV’K, FZ and AS: formal analysis. AS: supervision. OG-N
and AS: writing–original draft. OG-N, PV’K, FZ, GZ, VT and AS:
writing–review and editing. All authors contributed to the article
and approved the submitted version.ACKNOWLEDGMENTS
Wewould like to thank allmembers of the IVI and for their support
and helpful discussions. We are grateful to Daniela Niemeyer,
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